SCHEMBL5098101

SCHEMBL5098101

CCOC(=O)c1ccc(/C=N\O)[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.49
HTT P42858 2/20 0.49
MAPK1 P28482 1/20 0.49
LMNA P02545 3/20 0.44
RAB9A P51151 5/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 4/20 0.42
HSD17B10 Q99714 1/20 0.42
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
GABRB2 P47870 1/20 0.42
GABRA4 P48169 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5098107 1.00 HPGD (0.49) HPGDHTTMAPK1LMNARAB9A
SCHEMBL17472299 1.00 HPGD (0.49) HPGDHTTMAPK1LMNARAB9A
SCHEMBL14078157 0.82 GAA (0.49) HPGDMAPK1LMNARAB9ASMN1; SMN2
SCHEMBL359688 0.82 SMN1; SMN2 (0.47) HPGDHTTLMNARAB9ASMN1; SMN2
SCHEMBL1160497 0.79 LMNA (0.55) HPGDHTTLMNARAB9ASMN1; SMN2
SCHEMBL3595577 0.77 CA12 (0.49) HPGDHTTLMNARAB9ASMN1; SMN2
SCHEMBL3595574 0.77 CA12 (0.49) HPGDHTTLMNARAB9ASMN1; SMN2
SCHEMBL402047 0.74 LMNA (0.51) HPGDHTTMAPK1LMNARAB9A
SCHEMBL1231647 0.73 LMNA (0.50) HPGDHTTLMNARAB9ASMN1; SMN2
SCHEMBL1160309 0.73 HRH3 (0.53) HPGDHTTLMNARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7427683-B2 c-fms kinase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2008-09-23 US disclosed
EP-1812425-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-01 EP disclosed
WO-2006047479-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed
US-20050131022-A1 C-fms kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131022-A1 C-fms kinase inhibitors FLT3, FES, FGR HPGD 4870/4885HTT 2073/4885MAPK1 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.